Search company, investor...
Triangle Compounding Pharmacy company logo

Triangle Compounding Pharmacy


Loan | Acquired

Total Raised


About Triangle Compounding Pharmacy

Triangle Compounding Pharmacy (TCP) is an FDA-approved 503B Outsourcing Facility. TCP consists of two entities, a state regulated compounding pharmacy (503A) servicing the special pharmacy needs as prescribed for individual patients, and a separate FDA-inspected and approved Outsourcing Facility (503B) allowed to supply hospitals, medical research institutes, and clinical research organizations (CROs) nationwide.

Headquarters Location

3700 Regency Parkway Ste. 140

Cary, North Carolina, 27518,

United States


Missing: Triangle Compounding Pharmacy's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Triangle Compounding Pharmacy's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Triangle Compounding Pharmacy

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Triangle Compounding Pharmacy is included in 2 Expert Collections, including Pharma Supply Chain.


Pharma Supply Chain

1,258 items


Biopharma Tech

401 items

Latest Triangle Compounding Pharmacy News

United States Ophthalmic Compounding Pharmacies Industry Report to 2028 - Players Profiled Include Nora Apothecary, Lifecare Pharmacy, Avella Specialty Pharmacy and Triangle Compounding Pharmacy -

May 3, 2022

When a commercially available medicine does not fit the unique needs of an individual patient (human or animal), the drug is compounded by a certified pharmacist. When a patient may be unable to tolerate a commercially available drug, or when the particular formulation required may be unavailable, or the patient may require a treatment that is currently in short supply or has been withdrawn, compounding is carried out. Compounding is defined by the United States Pharmacopeia Convention (USP) as "the preparation, mixing, assembling, altering, packaging, and labelling of a drug, drug-delivery device, or device under a licensed practitioner's prescription, medication order, or initiative in the course of professional practice. The increasing launches of drugs and adoption of inorganic strategies such as collaborations by the key players operating in the market are expected to drive the market growth during the forecast period. For instance, in November 2020, Fagron Sterile Services, a U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA)-registered 503B outsourcing provider of sterile medications, launched its new innovative silicone-free bevacizumab (AVASTIN) injection using Groninger automation technology in collaboration with West Pharmaceutical Services, Inc., a U.S.-based pharmaceutical company. This silicon-free AVASTIN injection has a long shelf life of 150 days and can be administered safely for ophthalmic applications without depositing any unsafe silicon oil droplets into the eye. Key features of the study: This report provides an in-depth analysis of the U.S. ophthalmic compounding pharmacies market and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2021-2028), considering 2020 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players It profiles key players in the U.S. ophthalmic compounding pharmacies market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics The U.S. ophthalmic compounding pharmacies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. ophthalmic compounding pharmacies market Detailed Segmentation: Mitomycin Eye Drops Dry Eyes 503A Nora Apothecary

Triangle Compounding Pharmacy Frequently Asked Questions (FAQ)

  • Where is Triangle Compounding Pharmacy's headquarters?

    Triangle Compounding Pharmacy's headquarters is located at 3700 Regency Parkway, Cary.

  • What is Triangle Compounding Pharmacy's latest funding round?

    Triangle Compounding Pharmacy's latest funding round is Loan.

  • How much did Triangle Compounding Pharmacy raise?

    Triangle Compounding Pharmacy raised a total of $250K.

  • Who are the investors of Triangle Compounding Pharmacy?

    Investors of Triangle Compounding Pharmacy include Paycheck Protection Program and Panaceutics Nutrition.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.